Keenova Therapeutics plc announced today its Men's Health Month initiative, reaffirming its commitment to advancing men's health by hosting a Reddit "Ask Me Anything" (AMA) focused on Peyronie's ...

May 31 (Reuters) - Johnson & Johnson's (JNJ.N) ​prostate cancer drug Erleada used with hormone-blocking therapy six months ...

MEDSIR, a leading international oncology research company, has presented the final results of the ZZ‑FIRST study during an ...

Johnson & Johnson said its prostate cancer drug Erleada, when used with hormone-blocking therapy before and after prostate ...

Patients were nine times more likely to have little to no cancer remaining in the prostate after surgery, with a 20% reduction in the risk of developing metastasis ...

Despite contributing to half of all conception hurdles, male-factor infertility is rarely talked about. For former AFL player ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and ...

Perimenopause is the stage leading up to menopause and can start as early as the early 40s, or even the late 30s for some.

A lot of people think osteoporosis is only a women’s issue, but men can get it, too – especially as they get older, says Jim ...

NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) announced results from the final analysis of the Phase 3 PROTEUS study, evaluating apalutamide plus hormone therapy (androgen deprivation therapy, ADT ...

Johnson & Johnson's Erleada drug, combined with hormone therapy, significantly reduces the risk of prostate cancer spread and death in late-stage studies. Read more at straitstimes.com. Read more at ...

Johnson & Johnson's JNJ.N prostate cancer drug Erleada used with hormone-blocking therapy six months before and after prostate surgery improved the chances of eliminating the cancer and reduced the ...